Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria

Published:2022-01-02 Issue:1 Volume:27 Page:33-43
ISSN:1472-8214
Container-title:Expert Opinion on Emerging Drugs
language:en
Short-container-title:Expert Opinion on Emerging Drugs

Author:

Frieri Camilla¹²³,Peffault de Latour Régis¹²⁴,Sicre De Fontbrune Flore¹²

Affiliation:

1. French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Saint Louis Hospital, Paris, France

2. University Paris Diderot, Paris, France

3. Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy

4. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation, Leiden, Netherlands

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728214.2022.2031973

Reference100 articles.

1. Narrative Review: Paroxysmal Nocturnal Hemoglobinuria: The Physiology of Complement-Related Hemolytic Anemia

2. Historical aspects of paroxysmal nocturnal haemoglobinuria: ‘defining the disease’

3. 7 Paroxysmal nocturnal haemoglobinuria

4. Aplastic anemia: A common hematological abnormality among peripheral pancytopenia

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab;European Journal of Clinical Pharmacology;2024-05-30

2. Biomimetic proteolipid vesicles for reverting GPI deficiency in paroxysmal nocturnal hemoglobinuria;iScience;2024-03

3. Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies;Frontiers in Immunology;2023-04-04

4. Breakthrough Hemolysis Associated With COVID-19 Vaccination and Active COVID-19 Infection in a Patient With Paroxysmal Nocturnal Hemoglobinuria Maintained on Pegcetacoplan: A Case Report;Cureus;2023-03-16

5. A phase III, randomised, double‐blind, multi‐national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria;eJHaem;2022-12-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3